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Summal'y 
Resident pulmonary alveolar macrophages  (PAM) play an important role in the maintenance 
of immunological homeostasis in the lung via downmodulation of local T cell responses in the 
steady state. The present study demonstrates that this pathway for T cell suppression is reversible 
via granulocyte/macrophage colony-stimulating factor (GM-CSF). Thus, freshly isolated PAM 
strongly inhibit mitogen-induced T cell proliferation, and pretreatment of the PAM with cytokine- 
rich lung-conditioned medium (LCM) generated by exposure of lung to bacterial lipopolysaccharide 
(LPS) abrogated  this suppressive activity. LCM from lungs of normal and athymic nude mice 
exhibited identical activity. Moreover, the PAM-modulating activity of LCM was inhibited by 
blocking antibody specific for GM-CSF,  and the activity of LCM could be reproduced by 
recombinant GM-CSF. This suggests that secretion of GM-CSF by mesenchymal cells and/or 
macrophages  under stimulation from agents  such as LPS provides a potential mechanism for 
upregulation of local T cell responsiveness during acute inflammation.  In addition, experiments 
with a range of cytokines indicated that interleukin 4, transforming growth factor 31 and tumor 
necrosis factor o~ (TNF-oe) exhibited weaker (but significant) modulatory effects on PAM, and 
(in the case of TNF-c~) amplified the effects of GM-CSF. 
p~  sident pulmonary alveolar macrophages  (PAM) func- 
tion poorly as accessory cells for in vitro T cell activa- 
tion, generally expressing nil to low levels of APC activity 
(1-3),  and in many situations  actively suppressing  T  cell 
proliferation induced by antigen (4-8) or polyclonal stimuli 
(9, 10). This immunosuppressive  activity of PAM has been 
proposed to play an important role in maintaining immuno- 
logical homeostasis in the lung via a generalized "blanket" 
inhibition of T cell responses to nonpathogenic antigens de- 
posited on respiratory epithelial surfaces (reviewed in refer- 
ences 11-13). In principle,  the maintenance of a local im- 
munosuppressive milieu would serve to limit T cell-mediated 
tissue damage in the respiratory tract, which can potentially 
occur in response to constant exposure to inhaled environ- 
mental antigens/allergens  (13). 
Compelling evidence for the operation of such a mecha- 
nism in vivo has recently been provided via a series of studies 
on  selective depletion of PAM  in  mice and rats,  by  the 
intratracheal administration of a liposome-encapsulated mac- 
rophage-cytotoxic drug. PAM-deficient animals develop dys- 
regulation of local immune reactivity in the lung, and dis- 
play  gross  hyperresponsiveness  to  antigen  administered 
intratracheally  (14) or by aerosol (15, 16), characterized by 
the infiltration of large numbers of activated T cells and plasma 
cells into the lung parenchyma  (16). 
The potential value of such a steady-state control mecha- 
nism in downregulation of local T cell responses to inert en- 
vironmental antigens is self-evident. However, it is also ax- 
iomatic that countermeasures  should be available to allow 
reversal of this inhibition and hence mobilization of local T 
cell defenses, in the face of challenge with inhaled pathogenic 
(notably microbial) antigens. Local inflammation, leading to 
rapid dilution of the resident PAM population with recruited 
blood monocytes that are permissive to T cell activation (4, 
17, 18) and the influx of "young" dendritic cells that are ac- 
tive APC (19), provides one such potential pathway. How- 
ever, mononuclear cell recruitment is characteristic of the late 
(delayed) phase of the inflammatory response to microbial 
stimuli, and it is accordingly unlikely that this could provide 
a mechanism for upregulation of local T cell functions during 
the initial stages of the host response. 
In the study below, we demonstrate that exposure of resi- 
dent PAM to lung-conditioned medium (LCM) generated 
by  in  vitro  LPS  exposure  markedly  inhibits  the  lym- 
phocytostatic activity of resident PAM, and this process can 
be inhibited by a blocking antibody against GM-CSF. LCM 
from normal and athymic nude mice exhibit comparable PAM 
modulatory activity, suggesting that mesenchymal cells may 
be a major source of this activity during inflammation. We 
additionally demonstrated qualitatively similar (albeit smaller) 
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function, which in  the case of TNF-o~,  is  additive with 
GM-CSF. 
Materials  and Methods 
Animals.  Female,  specified  pathogen-free,  C3H/HeJ mice were 
used at 5-12 wk of  age (Animal Resource  Centre, Murdoch Univer- 
sity,  Western Australia). Age- and  sex-matched BALB/c and 
C57BL/6J mice were also used where indicated. 
Reagents and Cytokines.  LPS (type B Escherichia  coli 026:B6) was 
obtained from Difco Laboratories (Detroit, MI). Con A was pur- 
chased from Pharmacia (Uppsala, Sweden), and PHA was from 
Wellcome (Dartford, England). Recombinant  routine GM-CSF was 
obtained from Biosource International (CamariUo, CA). Purified 
natural human TGF-~1 and human rTNF-ol was obtained from 
Genzyme Corp. (Cambridge, MA). Recombinant murine TNF-cr 
was purchased from Boehringer Mannheim GmbH (Mannheim, 
Germany). Murine rlL-4 was a generous gift from Dr. P. Hodgkin 
(John Curtin School of Medical Research, Australian National 
University, Canberra). 
LPS-induced/-s  LCM was generated  as previously  described 
(20). Briefly,  BALB/c mice were given 5 #g LPS in saline intrave- 
nously and the lungs were removed  in toto 3 h later. After washing 
in PBS, each lung was placed in 5 ml RPMI and incubated for 
48 h at 37~  Conditioned media was pooled, heat inactivated at 
56~  clarified  by centrifugation, and sterilized  by passage through 
a 0.22-#m filter. FCS was added at a final concentration of 5%, 
and aliquots were stored at  -20~ 
Neutralizing Antibody  to  GM-CSE  Polyclonal  rabbit anti- 
routine GM-CSF  was a generous gift from Dr. K. Kumagai  (Depart- 
ment of Microbiology, School of Dentistry, Tohoku University, 
Sendai, Japan). This antibody has been shown previously not to 
crossreact with other routine CSFs (21). In preliminary  experiments, 
we ascertained that a 1:20 dilution of antibody could inhibit the 
proliferation of the GM-CSF/IL-3-dependent cell line FDCP-1 in- 
duced with recombinant murine GM-CSF, and this antibody con- 
centration was used to neutralize LCM activity. The antibody was 
preincubated with LCM for I h to 37~  before addition to PAM. 
Control antibody was a polyclonal  antisera against M-CSF (gener- 
ously provided by Dr. E. R. Stanley, Albert Einstein College of 
Medicine, Bronx, NY). 
Cell Preparation.  PAM were obtained as previously described 
(22). Briefly,  lungs were inflated with warm PBS containing 0.2% 
BSA (Commonwealth Serum Laboratories, Melbourne, Australia) 
and 12 mM lignocaine (Orion Laboratories, Welshpool, Western 
Australia) via cannulation of the trachea, and were lavaged at least 
15 times. Cells were collected by centrifugation and resuspended 
in KPMI 1640 (Gibco, Melbourne, Australia)  containing 5% FCS, 
hereafter referred to as medium. Lymph node cells (LNC) were 
obtained from a pool of mesenteric, inguinal, and brachial lymph 
nodes and were processed in PBS supplemented with 0.2% BSA 
and resuspended in medium for culture. 
Suppression of Mitogen-induced LNC Proliferation.  PAM at var- 
ious concentrations were incubated in triplicate in 200 #1 medium 
in 96-weU flat-bottomed  trays,  with medium, I.CM at 10% (vol/vol), 
or cytokines at the indicated concentrations, for 48 h (overall sur- 
vival in the PAM cultures over this period was ~>95%). Medium 
was removed, the cells washed three times in situ, and 4  x  10  s 
LNC added to each well in 200 #1 medium, containing Con A 
at 2.5 #g/ml; background control wells contained no Con A. Pre- 
liminary experiments demonstrated that the proliferation of LNC 
was unaltered in the presence of up to 50% of the various mac- 
rophage-conditioned media, confirming that there was no detect- 
able carry-over  of cytokine before the addition of LNC. Plates were 
incubated for 48 h, and [3H]thymidine  (Amersham, Sydney,  Aus- 
tralia) was added 16 h before harvesting the cells for determination 
of [3H]DNA synthesis (measured as cpm/culture). 
Results 
Preexposure to Lung-conditioned Medium Abrogates  the Ca- 
pacity of PAM to Inhibit T Cell Proliferation.  Data presented 
below are typical of a large series of experiments.  Freshly pre- 
pared resident PAM are able to completely suppress the Con 
A-induced proliferation of LNC when introduced into the 
cultures at a final density equivalent to >--5% of the total cells 
per well (Fig.  1 A). The same effect was observed using ei- 
ther PHA or Con A over a concentration range of 0.5-5.0 
/~g/ml, and is also readily demonstrable with antigen-induced 
T cell proliferation (data not shown). To ascertain whether 
lung-derived inflammatory  cytokines could modulate the sup- 
pressive capacity of PAM, we generated conditioned medium 
from LPS-stimulated whole lung (LCM) and preincubated 
PAM in the wells with LCM-supplemented medium for 24 
or 48 h before the addition of mitogen and LNC. Fig.  1 B 
shows that while PAM incubated for 48 h in medium alone 
maintain  their  capacity  to  suppress  the  mitogen-induced 
proliferation of LNC, PAM pretreated with LCM lose their 
ability to inhibit proliferation. Similar results were also ob- 
tained in BALB/c and C57BL/6J mice, and only minor differ- 
ences were observed when comparing 24- and 48-h LCM treat- 
ment (data not shown). The fact that LCM from nude and 
normal animals were equally potent in downmodulating the 
suppressive activity of PAM implies that lung T cells are not 
an important source of the agent(s) that mediate these effects. 
LCM  Modulation  of PAM  Immunosuppressive Activity  Is 
Abrogated  by  a  Polyclonal Anti-GM-CSF  Antibody  and  Is 
Reproduced by Recombinant GM-CSE  LCM is rich in GM- 
CSF (20), and so we examined whether GM-CSF itself was 
responsible for the modulating activity in LCM. Fig.  2 A 
shows that a polyclonal anti-GM-CSF was able to neutralize 
the majority of the PAM-modulating activity of LCM. The 
activity of the anti-GM-CSF antibody was inhibited by the 
inclusion of up to 100 ng/ml recombinant GM-CSF and the 
control sera directed against M-CSF had no effect on LCM 
activity (data not shown). In addition, we preincubated PAM 
with GM-CSF at various concentrations for the same time 
as LCM, and found that suppression  was reversible by GM- 
CSF in a dose-dependent fashion (Fig. 2 B). Maximal effects 
were observed  at 50 ng/ml (an average of 75%  inhibition 
of immunosuppressive activity over 12 experiments). 
GM-CSF Downmodulation of PAM-suppressive Activity Is En- 
hanced by TNF-cr.  The experiment detailed in Fig. 3 compares 
the immunomodulatory effects of GM-CSF with TNF-o~, 
TGF-3,  and IL-4.  The latter cytokines were used over a 
10-20-fold dose range (highest concentration only shown). 
All three cytokines were capable of partially abrogating the 
suppressive effects of PAM, the most active being TNF-c~, 
which was in the order of one-third as effective as GM-CSF. 
1774  GM-CSF  Inhibits Immunosuppressive  Activity  of Alveolar Macrophages o 
x 
e 
.q 
O 
O. 
CI 
300" 
2OO 
100 
A 
o  o'.6  5'.o   o.o 
B 
Number of PAM added to LNC cultures (as % total cells) 
Figure  1.  LCM inhibits the lymphocytostatic  activity 
of PAM. (A) Fresh FAM were titmted into 4  x  10  s LNC 
containing Con A (2.5/~g/ml) and the cultures were in- 
cubated  for  48  h  before  harvesting  to  determine 
[3H]thymidine  incorporation.  (B)  PAM  were  prein- 
cubated for 48 h in medium (n), or LCM prepared from 
normal (O) or athymic nude (O) mice, before the addi- 
tion of LNC and Con A. Results are ~pressed as the mean 
dpm  •  SD, minus background,  of nine individual  ex- 
periments. 
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Figure  2.  GM-CSF is responsible for the reversal of the suppressive ac- 
tivity of PAM by I.CM. (A) Medium, alone or supplemented  with either 
anti-GM-CSF,  LCM, or LCM  +  anti-GM-CSF (final dilution of 1:20), 
was preincubated  for 1 h at 37~  before their addition to PAM for 48 h, 
as detailed in Materials and Methods. PAM were washed, LNC +  Con A 
added,  and the cultures  incubated  for a further 48 h.  Replicate control 
wells included those without PAM (LNC alone), and LNC without Con A 
(bteg). **p  <  0.001 compared  with 10%  LCM.  (B) PAM were treated 
as in A  with medium, LCM, or GM-CSF for 48 h, washed,  and LNC 
+  Con A added and cultured as above. Results are expressed as the mean 
•  SD dpm of triplicate  wells.  *p < 0.01;  **p < 0.001 compared  with 
wells containing PAM incubated  with medium. 
A range of concentrations of IL-1 and IFN-fl were also tested, 
but proved ineffective (not shown). 
GM-CSF alone was capable of abrogating up to •75% 
of the immunosuppressive activity of PAM, but the combi- 
nation of GM-CSF and TNF-ol completely inhibited the ca- 
pacity of the PAM to suppress T  cell proliferation. Com- 
parable additive effects have not been observed using TGF-fll 
and IL-4 (data not shown). 
Discussion 
This is the first report to demonstrate that a specific  cytokine, 
viz. GM-CSF, is able to abrogate the immunosuppressive  ac- 
tivity of resident PAM. Given that we have used a non-specific 
inflammatory stimulant (LPS) to induce LCM and that both 
normal and athymic nude animals produce LCM with similar 
modulating activity,  it appears likely that the GM-CSF is 
of mesenchymal or macrophagic origin, and as such is pro- 
duced at an early stage of the host response after the initial 
inflammatory stimulus is encountered. GM-CSF has been 
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Figure  3.  GM-CSFoinduced downmodulation of PAM is enhanced by 
TNF-~. PAM were preincubated  for 48 h  as detailed in Materials  and 
Methods, with the cytokines indicated, washed, and then eocultured with 
LNC and mitogen. Results  are expressed as mean  _+  SD, minus back- 
ground, of triplicate  wells, and are representative of a series of seven ex- 
periments. 
1775  Bilyk and  Holt  Brief Definitive Report shown to be secreted by both airway epithelial cells (23) and 
macrophages (24) via the direct stimulatory effects of LPS, 
and in addition,  endothelial cells (25), fibroblasts (26), and 
airway epithelial cells (27) respond to cytokines released by 
LPS-stimulated macrophages (notably IL-1 and/or TNF-ot) 
via GM-CSF secretion. All of these cell types are abundant 
in lung tissue, and thus potentially contribute to local im- 
munoregulation  through  this pathway. 
While GM-CSF appears to be the most effective cytokine 
with respect to modulation of the immunoregulatory func- 
tions of PAM, it is clearly not unique in this regard, as TNF-c~, 
TGF-/St, and IL-4 all express low (but significant) modula- 
tory activity, and (at least in the case of TNF-o  0 can amplify 
the effects of GM-CSF. Both TNF-ot (28) and TGF-~I (29) 
have been shown to be released in high levels by activated 
macrophages at sites of inflammation  in the lung,  and may 
thus contribute in an autocrine fashion to the regulation of 
macrophage-mediated  T  cell activation in  these areas. 
In addition,  despite the apparent  lack of a contribution 
from T cells to the PAM modulatory activity of LCM in the 
present experiments,  earlier studies (30) have noted down- 
modulation of PAM suppression by lymphokine-rich T cell 
supernatants, but identification of the active agent(s) was not 
attempted. It appears likely from our current results that T 
cell-derived GM-CSF, IL-4, and TNF-ot may account for this 
activity. 
In relation to the mechanism of GM-CSF modulation of 
PAM activity, we have recently reported that  one pathway 
for PAM-mediated suppression of T  cell activation involves 
downmodulation of the function of the major APC popula- 
tion present in lung tissue (31).  Future studies are required 
to determine whether the effects of GM-CSF reported herein 
occur through  an identical  or parallel  pathway. 
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